EQ Stock Cash Flow Statements

Equillium Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Equillium Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31

operating activities:
net income	-5,739,000	-8,654,000	-5,794,000	-7,000	468,000	-2,734,000	-2,342,000
adjustments to reconcile net income to cash from operating activities:
depreciation	32,000	33,000	35,000	35,000	35,000	32,000
stock-based compensation	563,000	621,000	821,000	1,005,000	952,000	972,000	1,046,000
net unrealized (gain) loss on foreign currency transactions	-370,000	-49,000
amortization of investments	0	-14,000		-166,000	-241,000	-278,000
deferred revenue			-2,067,000	-6,363,000	-4,930,000	-2,368,000	-2,523,000
changes in operating assets and liabilities:
accounts receivable			5,009,000	885,000	-846,000	-1,313,000	34,000
prepaid expenses and other current assets	1,273,000	303,000	277,000	-10,000	2,528,000	-520,000	-750,000
accounts payable	1,745,000	381,000	-949,000	-843,000	1,756,000	-1,959,000	1,046,000
accrued expenses	-515,000	-786,000	-1,534,000	-1,858,000	1,239,000	-1,011,000	-1,710,000
right-of-use assets and lease liabilities	-2,000	-4,000	-5,000	7,000	-7,000	-4,000	24,000
net cash from operating activities	-3,013,000	-8,169,000	-3,299,000	-7,657,000	730,000	-8,800,000	-5,664,000
capex	0	-4,000	-4,000	0	-62,000	40,000	-35,000
free cash flows	-3,013,000	-8,173,000	-3,303,000	-7,657,000	668,000	-8,760,000	-5,699,000
investing activities:
purchases of property and equipment	0	-4,000	-4,000	0	-62,000	-19,000	-35,000
purchases of short-term investments			0	0	-10,289,000	-7,312,000	-17,531,000
maturities of short-term investments	0	4,500,000	6,000,000	12,000,000	9,000,000	4,500,000	12,000,000
net cash from investing activities	0	4,496,000	5,996,000	12,000,000	-1,351,000	-2,831,000	-5,566,000
financing activities:
proceeds from exercise of stock options	0	38,000
proceeds from issuance of common stock under atm facility, net of issuance costs	-16,000	53,000
net cash from financing activities	-16,000	91,000	73,000	0			79,000
effect of exchange rate changes on cash and cash equivalents	22,000	-1,000	-133,000	48,000	19,000	-17,000	-15,000
net decrease in cash and cash equivalents	-3,007,000	-3,583,000	2,637,000	4,391,000	-511,000	-11,648,000
cash and cash equivalents at beginning of period	0	18,085,000	0	0	0	23,216,000	0
cash and cash equivalents at end of period	-3,007,000	14,502,000	2,637,000	4,391,000	-511,000	11,568,000	-11,166,000
supplemental cash flow information:
atm facility issuance costs reclassed from other current assets	0	392,000
atm facility issuance costs in accrued expenses	-16,000	99,000
amounts included in accounts payable for purchases of property and equipment						59,000
net unrealized loss on foreign currency transactions					-224,000	383,000	-357,000
amortization of term loan discount and issuance costs							0
amortization of premium on investments
repayment of notes payable							0
common stock repurchased							0
proceeds from issuance of common stock under employee stock purchase plan			69,000	0			79,000
cash paid for interest
cash paid for income taxes
principal repayments on notes payable
acquired in-process research and development
amortization of premium and accretion of discounts on investments							-165,000
cash acquired in bioniz acquisition
net increase in cash and cash equivalents
fair value of bioniz assets acquired
issuance of common stock for bioniz acquisition
bioniz net liabilities assumed
depreciation and amortization
property and equipment in accounts payable
proceeds from issuance of common stock from follow-on offering, net of issuance costs
proceeds from espp purchases
right-of-use assets obtained in exchange for lease obligations
net unrealized gain on foreign currency transactions
non-cash consulting expense
realized gain on investments
right-of-use assets, operating leases
operating lease liabilities
proceeds from registered direct offering, net of offering costs
proceeds from issuance of common stock under atm, net of issuance costs
issuance of commitment shares to lincoln park pursuant to agreement
amortization/accretion of investments
proceeds from issuance of common stock under atm facilities, net of issuance costs
proceeds from issuance of notes payable, net of issuance costs
fair value of common stock warrants in connection with issuance of notes payable
atm issuance costs in accrued expenses
deferred rent
non-cash interest expense
change in fair value of biocon anti-dilution right
accretion of discount on investments
other non-cash income and expenses
proceeds from public offering of common stock, net of 2,123 issuance costs
proceeds from issuance of convertible promissory notes
proceeds from exercise of stock options, including early exercise
proceeds from espp purchase
conversion of convertible promissory notes into common stock
issuance of common stock to biocon pursuant to certain anti-dilution rights
non-cash research license expense
proceeds from public offering of common stock, net of 2,123,106 issuance costs
proceeds from issuance of convertible promissory notes related party
proceeds from issuance of common stock
supplemental disclosures of noncash activities:
issuance of common stock to biocon for license

We provide you with 20 years of cash flow statements for Equillium stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Equillium stock. Explore the full financial landscape of Equillium stock with our expertly curated income statements.

The information provided in this report about Equillium stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.